The EU Patent of the Best Selling Drug Has Expired, What Does it Mean for Biotech?
AbbVie’s Humira, a treatment for inflammatory disease and the world’s best-selling drug, is no longer…
AbbVie’s Humira, a treatment for inflammatory disease and the world’s best-selling drug, is no longer…
Cyltezo, an adalimumab biosimilar drug by Boehringer Ingelheim, has received the backing to be marketed…
Samsung Bioepis has announced the European Commission approved Imraldi, a biosimilar of AbbVie's Humira (adalimumab),…
Despite bringing a significant price reduction, biosimilars might lag in taking over the market of…
The European Commission has approved Truxima, the world's first biosimilar monoclonal antibody (mAb) with an…
The new guidelines from the FDA on interchangeability may bring the US biosimilar market up…
Sanofi is joining the biosimilars trend to challenge Roche's best-selling biological with a partnership that…
Boehringer Ingelheim is getting ready to launch a biosimilar for Roche's cancer blockbuster Avastin as…
As legal frameworks and regulatory pathways for biosimilars are in evolving all around the world,…
Sanofi and Regeneron (NY, US) have ruled their phase III clinical trial immunotherapy Sarilumab a…
Boehringer Ingelheim just announced positive Phase III results for its Humira biosimilar. The company is…
Biosimilars could be the future of the pharmaceutical industry, as the market could grow 10-fold…